Stroke is the leading cause of disability and mortality worldwide. Over 80% of all strokes in the world happen in the developing countries and studies conducted on these regions indicate remarkably higher fatality rates ([@B1], [@B2]). This neurological disorder imposes so many financial burdens on families and countries that it has become one of the most important healthcare issues in the world ([@B3]). According to the studies conducted in Iran, the incidence of stroke is 45 patients per 100,000 individuals among different populations ([@B4]). The main risk factors contributing to a stroke in Iran, like other parts of the world, include HTN (54%), hypercholesterolemia (15%), smoking (12%), IHD and DM ([@B5]).

Studies have demonstrated that stroke is associated with alterations in the balance of some trace elements. Indeed, trace elements are essential for maintaining the metabolism of neurons and glia ([@B6], [@B7]). Mg is an important trace element within the vascular system, and accumulating evidence has demonstrated that Mg has a key role in the pathogenesis of stroke and restoration of brain cells ([@B8], [@B9]). For example, animal studies have shown that Mg has a protective role in the integrity of blood brain barrier (BBB) and reduces edema after stroke as well as increases the antioxidant capacity in the lesion area through stimulation of antioxidant enzymes ([@B10]). The protective role of Mg at different age categories is discussed in details by Ingram Lingam and Nicola H Robertson in the review ([@B11]). It has also been shown that subjects with stroke have abnormalities in their serum and CNS Mg levels ([@B12]). Some studies indicate that a low serum Mg level promotes the risk of ischemic stroke, partially through affecting type 2 diabetes, HTN, and metabolic syndrome ([@B13], [@B14]) although some have suggested that Mg is independently associated with cerebrovascular diseases ([@B15], [@B16]). However, few, if any, studies have ever examined Mg status among ischemic and hemorrhagic stroke patients. Therefore, the purpose of this study was to investigate the serum level of Mg among ischemic and hemorrhagic stroke patients and its relationship with the risk factors of these subtypes of stroke such as HTN, IHD, DM, and HLP, as well as the severity of stroke at admission and discharge to find whether Mg status can be introduced as a novel predictor in these patients.

Methods
=======

**Study population:**This cross-sectional analytic study was performed on 447 stroke patients recruited from Ayatollah-Rouhani Hospital in Babol, Iran. This hospital is the main center for admission of stoke patients in Babol and the surrounding areas, and the patients of the present study were chosen from among those referring to the hospital from May 2015 to May 2017. Written consent was obtained from all subjects. The study was approved by the Ethics Committee of the Babol University of Medical Sciences (3407-9542120). Demographic characteristics of patients, type and severity of stroke, risk factors such as HTN, IHD, DM, HLP, and smoking were recorded in a checklist. The study population was divided into two main groups (ischemic stroke group and hemorrhagic stroke group), and each main group was further divided into two sub-groups, namely: embolic and thrombotic for the ischemic group, and intracerebral hemorrhagic (ICH) and sub-arachnoid hemorrhagic (SAH) for the hemorrhagic group. Stroke was diagnosed based on the neurological examination and neuroimaging findings. Computed tomography (CT) or magnetic resonance imaging (MRI) was performed for all patients. Although CT scans determine subarachnoid blood in patients with CT-negative, lumbar puncture (LP) was performed to determine subarachnoid blood([@B4]). Diagnosis of stroke and its types was made according to the criteria followed in epidemiological studies of stroke ([@B17]). Definitive diagnosis of all stroke cases was confirmed by the neurologist responsible to do the project.

Severity of stroke was determined on the basis of NIH Stroke Scale (NIHSS) criteria, ([@B18]) where score ≤ 8 mild , 9 -- 15 moderate and ≥ 16 severe stroke. HTN was defined as more than 140 mm-Hg for systolic blood pressure (SBP) or more than 90 mm-Hg for diastolic blood pressure (DBP). DM was defined as fasting blood sugar (FBS) more than 126 mg/dL, HLP as deregulated lipid profile patients including low level of HDL, high level of LDL and high triglyceride ([@B19]), and history of ischemic heart disease (IHD) was obtained from background information, history of cardiac medications, and ECG. Finally, patients were categorized as smokers if they had smoked at least 5 cigarettes per day in the last year.

**Exclusion criteria:**Exclusion criteria for the patients were cases with hemiparesis or any focal neurological findings other than stroke including head trauma, metabolic encephalopathy, brain abscess, brain tumor, migraine attacks, and seizure ([@B19]). Transient ischemic attack (TIA) cases were also excluded from the study. Besides, patients with renal failure, liver disorders, and those taking corticosteroid drugs were excluded.

**Blood sampling and laboratory assessment:**Serum samples were taken immediately after diagnosis of stroke and placed at -20˚C until use. Biochemical parameters including triglyceride (TG), FBS, and total cholesterol were measured using a commercially available kit. The serum Mg level was measured by Pars Azmoon kit (Pars Azmoon corporation, Iran, cat: 126500) according to the protocol. Magnesium was assessed based on xylidyl-blue which at alkaline ph Mg and xylidyl-blue produce a purple colored complex. The colorimetric technique was used to determine the concentration of Mg at 450 nm. The normal level of Mg was considered between 1.5 and 2.3 g/dl, and the values less than 1.5 g/dl were considered as low level while values more than 2.3 g/dl were considered as high level([@B19]). The serum Mg levels were measured along with other laboratory tests in the clinical laboratory of Ayatollah-Rouhani Hospital in Babol.

**Statistical analysis:**In our study, the statistical data were analyzed quantitatively and qualitatively using SPSS (Version 24.0; SPSS Inc., Chicago, IL, USA). To determine the association of Mg serum levels with prognosis of stroke, we used chi-square test, and the relationship between other variables influencing the type of stroke and Mg serum status was examined by Fisher\'s Exact Test with calculation of odds ratio (OR) and 95% confidence interval (95% CI). Furthermore, p\<0.05 were considered as significant. The diagnostic accuracies of Mg for the discrimination of ischemic stroke and hemorrhagic stroke patients were analyzed by receiver operating characteristic curves (ROC). The optimal cut-off values were selected based on the maximum value of sensitivity and specificity.

Results
=======

Included in this cross-sectional study were 447 stroke patients of whom, 225(50.3%) were males and 222 (49.7%) were females. As with the type of stroke, 374 had the ischemic type, of whom 170 patients were embolic and the rest were thrombotic while of the 73 having the hemorrhagic type, 26 were SAH and 47 were ICH. With regard to the relationship between stroke types and risk factors, we observed that there was a significant difference between HTN and the types of stroke and their subgroups (thrombotic/embolic, ICH/SAH) (P=0.026, 0.043 and 0.003, respectively). In addition, 29 patients having ICH stroke and 9 having SAH stroke had diabetes, while 18 having ICH as well as 17 having SAH did not have this disorder. Thus, according to this main risk factor, there was a significant difference between the subtypes of hemorrhagic stroke and DM (P=0.027). Moreover, considering the severity and status of stroke at discharge, we found a significant difference between the severity of stroke at the time of discharge in two types of stroke (P=0.034) and the subtypes of ischemic stroke (P=0.005). We also observed that 36.9% of the ischemic stroke patients and 76.7% of those having the hemorrhagic type had hypomagnesemia. Besides, the mean±SD serum levels of Mg in ischemic and hemorrhagic groups were 1.63±0.42 mg/dl, and 1.31±0.37 mg/dl respectively, and there was a significant difference between the two types of stroke with serum Mg status (P=0.001) while we did not find significant difference between serum Mg levels and both subtypes of ischemic as well as the hemorrhagic stroke (P=0.139, 0.426, respectively) ([table 1](#T1){ref-type="table"}).

The results of our data demonstrated that the only significant difference in serum levels of Mg was between both genders of thrombotic stroke patients (P=0.049). According to our findings, there was a significant association between the subtypes of ischemic stroke (i.e., thrombotic and embolic) and HTN, so in the thrombotic patients having a history of HTN as opposed to thrombotic patients not having a history of HTN, serum levels of Mg was low, and these findings were also observed for embolic patients (both of them P\<0.001).

Moreover, there was a significant association of serum Mg levels with severity of ischemic stroke in comparison with hemorrhagic stroke at the time of discharge (P\>0.05), and we also found that serum Mg levels were significantly associated with the severity of ischemic stroke at the time of discharge in thrombotic (P\<0.001) and embolic patients (P=0.003), but they were not significantly associated with severity at the time of discharge in the hemorrhagic group (P\>0.05).

Meanwhile, we did not find a significant association between serum status of Mg with severity of stroke at the time of admission in ischemic and hemorrhagic groups plus their sub-groups (P\>0.05 all of them). Besides, there were significant relationships between serum Mg levels with DM only in thrombotic groups (P=0.012). Finally, of the 447 stroke cases, only in the subgroup of embolic, Mg serum status was associated with HLP (P=0.012) ([table 2](#T2){ref-type="table"}). We used logistic regression test to determine the effect of the measured variables on the risk of ischemic stroke. These findings demonstrated that serum Mg status is a risk factor for ischemic stroke and has a significant role (P=0.006, OR=5.43 and CI 95%= 1.61-18.31) ([table 3](#T3){ref-type="table"}).

In addition, to estimate the diagnostic accuracy of Mg for the distinction of ischemic stroke patients from those having hemorrhagic stroke, ROC analysis was performed and the results were presented in figure 1.  According to the ROC analysis, the cutoff value of 1.35 mg/dl serum levels of Mg showed the best diagnostic accuracy for discriminating ischemic stroke patients from hemorrhagic ones: AUC=0.71, P\< 0.001 and 95% CI = (0.634 -- 0.758).

###### 

Frequency of stroke patients according to gender, severity of stroke and distribution of risk factors, as well as the mean±standard deviation (SD) serum levels of Mg in type of stroke and subtype of ischemic (embolic and thrombotic) as well as hemorrhagic of stroke (ICH and SAH)

                               **Ischemic of stroke**   **Hemorrhagic of stroke**                                                
  ---------------------------- ------------------------ --------------------------- ----------- ---------- ---------- ---------- -------
  Gender                       male                     57.4(109)                   42.6(81)    0.261      68.6(24)   31.4(11)   0.473
  female                       51.6(95)                 48.4(89)                    60.5(23)    39.5(15)                         
  HTN                          Yes                      60.5(98)                    39.5(64)    0.043      78.6(33)   21.4(9)    0.003
  NO                           50(106)                  50(106)                     45.2(14)    54.8(17)                         
  IHD                          Yes                      50(81)                      50(81)      0.123      64.9(24)   35.1(13)   0.931
  NO                           58(123)                  42(89)                      63.9(23)    36.1(13)                         
  HLP                          Yes                      56.5(14)                    43.5(170)   0.45       62.1(18)   37.9(11)   0.737
  NO                           52.6(100)                47.4(90)                    65.9(29)    34.1(15)                         
  DM                           Yes                      57.1(96)                    42.9(72)    0.362      76.3(29)   23.7(9)    0.027
  NO                           52.4(108)                47.6(98)                    51.4(18)    48.6(17)                         
  Smoking                      Yes                      50.3(73)                    49.7(72)    0.194      63.6(21)   36.4(12)   0.904
  NO                           57.2(131)                42.8(98)                    65.0(26)    35.0(14)                         
  Severity in admission time   Mild                     54.1(146)                   45.9(124)   0.348      68.0(34)   32.0(16)   0.424
  Moderate                     52.4(44)                 47.6(40)                    60.0(12)    40.0(8)                          
  Severe                       70.0(14)                 30.0(6)                     33.3(1)     66.7(2)                          
  Severity in discharge time   Mild                     47.6(89)                    52.4(98)    0.034      63.0(17)   37.0(10)   0.632
  Moderate                     60.7(65)                 39.3(42)                    72.2(13)    27.8(5)                          
  Severe                       58.6(34)                 41.4(24)                    68.8(11)    31.3(5)                          
  death                        72.7(16)                 27.3(6)                     50.0(6)     50.0(6)                          
  Mg (mg/dl)                   Mean±SD                  Mean±SD                     0.139       Mean±SD    Mean±SD               
  1.60±0.44                    1.67±0.40                1.28±0.38                   1.36±0.41   0.426                            

*HTN: hypertension, IHD: ischemic heart disease, HLP: hyperlipidemia, DM: Diabetes Mellitus.*

*P.value \*: indicating significant difference between thrombotic and embolic patients in ischemic of stroke.*

*P.value \*\*: indicating significant difference between ICH and SAH patients in hemorrhagic of stroke.*

###### 

Stroke types, risk factors and severity, considering of serum levels of Mg

  **Variable**   **Serum levels of Mg (%)**   **P.value**                          
  -------------- ---------------------------- ------------- ---------- ----------- -----------
  Ischemic       thrombotic                   Female        31.6(30)   68.4(65)    0.049\*
  male           45.0(49)                     55.0(60)                             
  Embolic        Female                       33.7(70)      66.3(59)   0.774       
  male           35.8(29)                     64.2(52)                             
  Hemorrhagic    ICH                          Female        73.9(17)   26.1(6)     0.231
  male           80.9(38)                     19.1(9)                              
  SAH            Female                       60.0(9)       40.0(6)    0.234       
  male           81.8(9)                      18.2(2)                              
                 HLP                                                               
  Ischemic       thrombotic                   Negative      36.0(36)   64.0(64)    0.433
  positive       41.3(43)                     58.7(61)                             
  Embolic        negative                     43.3(56.7)    56.7(51)   0.012\*     
  positive       25.0(20)                     75.0(60)                             
  Hemorrhagic    ICH                          negative      86.2(25)   13.8(4)     0.236
  positive       72.2(13)                     27.8(5)                              
  SAH            negative                     66.7(10)      33.3(5)    0.741       
  positive       72.7(8)                      27.3(3)                              
                 HTN                                                               
  Ischemic       thrombotic                   Negative      25.5(27)   74.5(79)    \<0.001\*
  positive       53.1(52)                     46.9(49)                             
  Embolic        negative                     21.7(23)      78.3(83)   \<0.001\*   
  positive       56.3(36)                     43.8(28)                             
  Hemorrhagic    ICH                          negative      64.3(9)    35.7(5)     0.060
  positive       87.9(29)                     12.1(4)                              
  SAH            negative                     70.6(12)      29.4(5)    0.837       
  positive       66.7(6)                      33.3(3)                              
                 Severity in discharge time                                        
  Ischemic       thrombotic                   Mild          24.7(22)   75.3(67)    \<0.001\*
  Moderate       40.0(26)                     60.0(39)                             
  Sever          73.5(25)                     26.5(9)                              
  death          37.5(6)                      62.5(10)                             
  Embolic        Mild                         24.5(24)      56.7(51)   0.003\*     
  Moderate       40.5(17)                     75.0(60)                             
  Sever          58.3(14)                     41.7(10)                             
  death          66.7(4)                      33.3(2)                              
  Hemorrhagic    ICH                          Mild          64.7(11)   35.5(6)     0.145
  Moderate       92.3(12)                     7.7(1)                               
  Sever          81.8(9)                      18.2(2)                              
  death          100.0(6)                     0.0(0)                               
  SAH            Mild                         40.0(4)       60.0(6)    0.07        
  Moderate       80.0(4)                      20.0(1)                              
  Sever          100.0(5)                     0.0(0)                               
  death          83.3(5)                      16.7(1)                              
                 IHD                                                               
  Ischemic       Thrombotic                   Negative      35.0(43)   65.0(80)    0.174
  positive       25.8(23)                     55.6(45)                             
  Embolic        negative                     25.8(23)      74.2(66)   0.011\*     
  positive       44.4(36)                     55.6(45)                             
  Hemorrhagic    ICH                          negative      69.6(6)    30.4(7)     0.060
  positive       91.7(23)                     8.3(2)                               
  SAH            negative                     46.2(6)       53.8(7)    0.012\*     
  positive       92.3(12)                     7.7(1)                               
                 DM                                                                
  Ischemic       Thrombotic                   Negative      30.6(33)   69.4(75)    0.012\*
  positive       47.9(46)                     52.1(50)                             
  Embolic        negative                     32.7(33)      67.3(66)   0.512       
  positive       37.5(27)                     62.5(45)                             
  Hemorrhagic    ICH                          negative      83.8(15)   16.7(3)     0.733
  positive       79.3(23)                     20.7(6)                              
  SAH            negative                     76.5(13)      23.5(4)    0.272       
  positive       55.6(5)                      44.4(4)                              
                 Severity in admission time                                        
  Ischemic       thrombotic                   Mild          34.2(50)   65.8(96)    0.094
  Moderate       47.4(21)                     52.3(23)                             
  severe         26.6(8)                      18.4(6)                              
  Embolic        Mild                         32.2(40)      67.7(84)   0.205       
  Moderate       37.5(15)                     62.5(5)                              
  severe         66.7(4)                      33.3(2)                              
  Hemorrhagic    ICH                          Mild          85.3(29)   14.7(5)     0.237
  Moderate       75.0(9)                      25.0(3)                              
  severe         0(0)                         100(1)                               
  SAH            Mild                         56.3(9)       14.7(5)    0.234       
  Moderate       87.5(7)                      12.5(1)                              
  severe         100(2)                       0(0)                                 

Intracerebral hemorrhage (*ICH*), *Subarachnoid hemorrhage* (*SAH*), Hyperlipidemia (HLP), Hypertension(HTN), Ischemic heart disease(IHD), Diabetes mellitus (DM). P.value\*: indicating significant difference between groups (\<0.05).

###### 

The risk of ischemic stroke with adjusted variables by logistic regression test

  **Variable**                            **Odds Ratio (OR)**   **Confidence interval 95%**   **P.value**
  --------------------------------------- --------------------- ----------------------------- -------------
  Gender                                  0.85                  0.28-2.36                     0.79
  Mg                                      5.43                  1.61-18.31                    0.006
  Mild stroke severity at admission       1.00                  \-                            0.43
  Moderate stroke severity at admission   0.98                  0.35-2.69                     0.96
  Severe stroke severity at admission     5.15                  0.41-63.8                     0.20
  Mild stroke severity at discharge       1.00                  \-                            0.47
  Moderate stroke severity at discharge   0.58                  0.16-2.16                     0.42
  Severe stroke severity at discharge     1.56                  0.52-4.67                     0.43
  Death stroke severity at discharge      2.08                  0.30-14.51                    0.45
  HTN                                     0.82                  0.29-2.36                     0.71
  IHD                                     0.95                  0.38-2.36                     0.91
  DM                                      1.29                  0.52-3.19                     0.57
  HLP                                     0.59                  0.22-1.56                     0.29
  Smoking                                 2.60                  0.86-7.86                     0.09

Discussion
==========

To the best of our knowledge, this is the first study to investigate the relationship between the serum levels of Mg and demographic features, risk factors, and severity among ischemic and hemorrhagic stroke patients. The results of our  study demonstrated that there was a significant difference between the Mg serum level detected in the ischemic stroke group and that of the hemorrhagic stroke patients. In contrast to our study, Bayir et al. reported that mean Mg serum status did not have a significant difference in ischemic and hemorrhagic stroke patients in comparison with a healthy group (P=0.74), which seems to be due to the small sample size ([@B20]). Similarly, Koksaldi et al. indicated that in acute stroke patients, the Mg serum levels did not have any statistically significant difference with those of the healthy group, and there was only a significant correlation between serum and CSF Mg levels ([@B21]). Additionally, another study reported that the mean serum Mg level in 200 patients with acute ischemic stroke was 1.71±0.51mg/dl of whom 32% had hypomagnesemia([@B22]), while the mean Mg serum level in our study was 1.58±0.43 mg/dl of whom 37% had low Mg. Furthermore, Karadas et al. found that serum Mg levels were significantly lower in 26 patients with acute hemorrhagic stroke compared with 29 healthy individuals([@B23]). However, our data showed that the mean of Mg levels in ischemic patients were higher than that of the hemorrhagic ones. These discrepancies between the studies mentioned may be due to geography of the living place, lifestyles and diet differences, which can significantly affect the results. However, the difference between the mean of Mg levels in different types of stroke may have a physiopathologic basis, which may be considered for future studies.

Besides, we did not find any significant difference in serum Mg status between the subgroups of ischemic stroke (i.e., thrombotic and embolic) and those of hemorrhagic stroke (i.e., ICH and SAH). Furthermore, in a meta-analysis study, a modest but statistically significant inverse association between Mg intake and risk of stroke was observed. Daily intake increment of 100 mg Mg/d was associated with an 8% reduction in the risk of total stroke, and Mg intake was inversely associated with risk of ischemic stroke but not with ICH and SAH ([@B14]), which was consistent with our results.

Our findings also showed that the differences in Mg levels were significantly associated with gender in thrombotic patients and that HLP was significantly associated with Mg serum status in embolic patients. In this line, Akarolo-Anthony et al. observed that among women with ischemic stroke, the median status of Mg was not different in comparison with healthy individuals. They showed that there was no significant association between plasma level of Mg and the risk of total ischemic stroke, and when adjusted for HbA1c, history of DM, history of HTN, coronary heart disease, total/HDL cholesterol did not alter the risk estimates (RR=1.34, P.trend= 0.19)([@B24]). In addition, Ohira et al. in a cohort study observed that status of serum Mg positively correlated with both LDL- and HDL-cholesterol levels in ischemic stroke patients. Furthermore, higher serum Mg levels were associated with lower prevalence of HTN and DM at baseline, and baseline serum Mg was inversely correlated with blood pressure and the prevalence of HTN and DM(13). Recently, a study reported that acute ischemic stroke patients with lower Mg levels also differed in lipid profile (higher HDL-cholesterol levels, but lower TG levels, and LDL-cholesterol levels), and that a significant correlation between Mg status at admission and gender and risk factors such as cigarette smoking, history of HTN, DM, coronary heart disease([@B25]). HTN and DM could be mediators between serum Mg and the incidence of different types of stroke. Besides, these associations have also been detected in other prospective studies ([@B26]-[@B28]). Thus, the results of our study were similar to the studies of Ohira et al. and Shoujiang You et al.

Difference in Mg levels was significantly associated with HTN in both subgroups of ischemic stroke, but not with both subtypes of hemorrhagic stroke. However, according to the findings in DM patients, we observed that there was a significant association between the status of Mg and the presence or absence of DM only in thrombotic patients, as opposed to other subgroups of stroke. With respect to the results of a previous study that reported the Mg levels to be associated with DM and HTN in ischemic stroke patients([@B29], [@B30]), we illustrated that Mg levels had a significant association with HTN in both subgroups of ischemic stroke and it was correlated with DM only in one subgroup of ischemic stroke (i.e., thrombotic patients). Given this finding, hypomagnesemia should be taken into account considering the relationship between serum Mg levels and DM and HTN in ischemic stroke patients, and this could be a subject for future studies.

Several studies have investigated the effect of baseline Mg on stroke outcome. The role of serum Mg levels in ischemic recovery, however, remains controversial and deserves further investigation([@B31], [@B32]). Severity of stroke at discharge is an important prognostic factor, and we found in both subgroups of ischemic stroke that there was a significant association between Mg serum levels and severity at discharge, but not at admission. Currently, there are few studies conducted in this line of inquiry. However, Siegler et al. reported that there were no significant differences in severity of stroke between patients with low admission Mg relative to patients with normal-to-high serum Mg levels, and it was proposed that Mg groups at baseline were not predictive of poor functional outcome, death or discharge disposition([@B33]). Therefore, future studies are needed to shed more light on the association between Mg and severity at admission and discharge times. If the relationship between hypomagnesemia and stroke severity is confirmed, the question arises whether hypomagnesemia leads to severe stroke or more severe stroke will lead to hypomagnesemia.

A more recent study has found that the plasma status of Mg was negatively associated with the risk of cardiovascular outcomes including coronary heart disease and atrial fibrillation ([@B34], [@B35]). Additionally, it appeared that serum Mg level was inversely correlated with von Willebrand factor status, which in turn was positively associated with the incidence of ischemic stroke ([@B36]). Hence, our findings indicate that serum Mg levels had a significant association with IHD in embolic ischemic stroke and in SAH of hemorrhagic stroke, which is similar to the results of the mentioned studies.

Considering the findings about the relationship between stroke types and its risk factors, we found that there was a significant difference between HTN with the type of stroke and its subgroups, and that DM as the main risk factor of stroke, had a significant difference with regard to the subtypes of hemorrhagic stroke. Moreover, there was a significant difference in the severity of stroke at discharge in terms of the two types of stroke and the subtypes of ischemic stroke. In this line, many studies have demonstrated that stroke and its subgroups are associated with some risk factors such as HTN, DM, IHD, and HLP ([@B24], [@B25], [@B33]), while our data did not show a significant association between IHD and HLP with types of stroke and their subgroups. In this regard, Ahangar et al. reported that hypertension was significantly associated with hemorrhagic stroke, while dyslipidemia was more associated with ischemic stroke. Meanwhile, they found that stroke was more prevalent in females ([@B2]). However, in the present study, from the risk factors studied, the HTN similarly was significantly associated with various types of stroke, while HLP, gender, IHD and smoking did not have significant association with the different types of stroke.

According to the ROC analysis, we determined the diagnostic accuracy of the measured Mg and extracted the related cut-points and data. Based on the results of the ROC curve analysis, the cutoff value of 1.35 mg/dl serum levels of Mg showed the best diagnostic accuracy for discriminating ischemic stroke patients from hemorrhagic ones with the AUC value of=0.71 which makes Mg consider as a potential marker. Definitely evaluating the diagnostic accuracy of Mg in large and longitudinal studies can open a new window for possible more applications of these molecules in the clinic. However, further large scale studies are needed to verify our results, and there are still some potential limitations that merit considerations. For instance, our study did not have healthy individuals as a control group to compare patients with different types of stroke with healthy persons. Furthermore, the short follow-up time is another limitation. Despite these limitations, the relatively high number of studied patients in comparison with similar studies on this topic was one of the strengths of this study.

The mean of Mg levels in ischemic patients was significantly higher than hemorrhagic type. Difference in Mg levels was associated with gender in thrombotic patients, and HLP was associated with serum status of Mg in embolic patients. Besides, serum Mg levels were correlated with IHD in embolic and SAH patients and DM only in thrombotic patients. Moreover, serum Mg status was associated with the severity of ischemic stroke at discharge in ischemic stroke patients. Mg levels had the best AUC, sensitivity and specificity for discrimination of ischemic patients from hemorrhagic ones.
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